Table 3.
The examples of Res–loaded delivery systems for anticancer therapy.
| DDS | Material | Size [nm] | EE [%] | Preparation Method | Location | Status | Ref. |
|---|---|---|---|---|---|---|---|
| NPs | Au | 30.75 ± 3.41 | n/d | Reduction with chloroauric acid | Breast | In vitro—MCF-7 cells | [133] |
| NPs | PCL | 132 ± 4 a | 98.4 ± 0.3 a | Interfacial deposition | Skin | In vitro—B16F10 cells In vivo—mice |
[134] |
| NPs | PLC, PLGA, PEG | 150 | 83.30 ± 13.47 | Nanoprecipitation | Prostate | In vitro—DU-145, PC-3 and LNCaP cells | [135] |
| NPs | PLGA | 202.8 ± 2.64 | 89.32 ± 3.51 | Solvent displacement | Prostate | In vitro—LNCaP cells | [136] |
| NPs | CB | n/d | n/d | N/d | Lung | In vitro—A549 cells | [137] |
| NPs | FA-HSA | 102.1 ± 4.9 | 98.36 | High pressure fluid nano-homogeneous emulsification | Liver | In vitro—HepG2 cells In vivo—mice |
[138] |
| NPs | Pluronic F127 block copolymer, vitamin E-TPGS | 179 ± 22 | 73 ± 0.9 | Emulsification | Breast | In vitro—MCF-7, MDA-MB-231, MCF-10A cells |
[139] |
| SLNPs | SA, saturated monoacid, triglyceride, Myrj52 | 168 ± 10.7 | n/d | Emulsification and low-temperature solidification | Breast | In vitro—MDA-MB-231 cells | [140] |
| SLNPs | Apolipoprotein E, DSPE, palmitic acid | 217.1 ± 5.8 | 98.9 ± 0.6 | High shear homogenization | Brain | hCMEC/D3 cells | [141] |
Au—gold; CB—carbon black; CS—chitosan; DDS—drug delivery system; DSPE—1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; FA—folic acid; HSA—human serum albumin; Myrj52-polyoxyethylene (40) stearate; PCL—poly(ε-caprolactone); PLGA—poly(lactide-co-glycolide); SA—stearic acid. a nanoparticles containing 10 mg of Res.